In a space full of “zero revenue, telling stories, betting on the future,” Intuitive Surgical (ISRG) is an outlier: among embodied-AI names, it’s one of the longest-profitable — decades of earnings, a proven model, a real data flywheel — and it’s the purest-model surgical-robot leader of the bunch. (Deere and defense autonomy are also earning in this series; but for “profitable for decades, compounding purely on robot consumables,” ISRG is the benchmark.)

But it carries a label that scares value investors off — expensive. Forward P/E ~40–45x, trailing ~60x, above medtech peers. So many say: great company, too pricey, wait for a pullback.

This piece wants to flip that view: ISRG isn’t “absurdly expensive” — it’s “expensively justified.” And the 2026 drawdown is its rare “not-so-expensive” window.

The moat, nailed down in numbers

Why it earns its price — a textbook razor/blade model:

• Installed base of 11,395 systems, market share 60%+ — dominant in soft-tissue surgical robotics.
• Recurring revenue 86% — it makes money not mainly from selling machines, but from instruments, accessories, and service per procedure.
• Instrument + accessory revenue ~$1,880 per procedure, still rising year over year.

The system is the razor (installed at low or subsidized margin); consumables and service are the blade (86% recurring, ~$1,880 per procedure and climbing). Once a hospital installs, trains surgeons, and builds workflow, switching costs are enormous — re-procurement, re-training, clinical risk. That’s data flywheel + high switching cost + installed-base compounding, and it’s been profitable for decades — not an option.

Better still, the upgrade cycle is just starting: the newest da Vinci 5 is only ~13% of the installed base — the other 87% hasn’t upgraded — with higher utilization and higher per-procedure consumables ahead. A multi-year tailwind with high visibility.

“Expensive” was never a reason to skip a quality compounder

So how to read the “expensive”?

The key insight: for a quality compounder like ISRG, you almost never get “cheap” — only “not so expensive.” Its five-year median multiple is higher than today’s — versus its own history, the current multiple is actually a discount. What compressed it was the “competition is finally here” narrative (Medtronic’s Hugo, J&J’s Ottava), which drove a ~28% drawdown in 2026.

But see the competition clearly: over the next 2–3 years, Hugo/Ottava are more of a valuation suppressor than a fundamental threat — ISRG installs 431 systems in a single quarter, and the installed-base gap is still widening. Competition hasn’t dented earnings; it’s just lowered the multiple the market will pay.

For a long-term holder who believes in razor/blade plus the upgrade cycle, every drawdown that “competition panic” creates is a better entry than its own history usually offers — because the fundamentals (installs, procedures, consumables) keep compounding on plan; only the multiple is pinned down by sentiment.

Great companies rarely go on sale. When one gets de-rated on a worry that won’t bite for 2–3 years, that’s usually not danger — it’s opportunity.

Have you ever skipped a quality compounder because it was “too expensive”? Did it ever come back down?

(Independent industry and educational research, not investment advice. Companies named are illustrative examples, not recommendations. Data is from public sources and may change. The author and affiliates may hold positions in securities mentioned.)

— Adapted from Embodied Intelligence Investing, Deep Dive VIII: ISRG Deep Case

#IntuitiveSurgical #SurgicalRobotics #EmbodiedAI